GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (STU:8QQ) » Definitions » Stock Based Compensation

AbCellera Biologics (STU:8QQ) Stock Based Compensation : €62.48 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is AbCellera Biologics Stock Based Compensation?

AbCellera Biologics's Stock Based Compensation for the three months ended in Jun. 2024 was €16.52 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2024 was €62.48 Mil.


AbCellera Biologics Stock Based Compensation Historical Data

The historical data trend for AbCellera Biologics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics Stock Based Compensation Chart

AbCellera Biologics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
Get a 7-Day Free Trial 0.80 6.91 27.13 46.71 58.85

AbCellera Biologics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.14 14.86 15.09 16.02 16.52

AbCellera Biologics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €62.48 Mil.


AbCellera Biologics Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


AbCellera Biologics Business Description

Traded in Other Exchanges
Address
2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

AbCellera Biologics Headlines

No Headlines